STEMdiff™ Cardiomyocyte Expansion Kit

Serum-free kit for the expansion of early-stage human PSC-derived cardiomyocytes

STEMdiff™ Cardiomyocyte Expansion Kit

Serum-free kit for the expansion of early-stage human PSC-derived cardiomyocytes

From: 661 USD
Catalog #
(Select a product)
Serum-free kit for the expansion of early-stage human PSC-derived cardiomyocytes
Add to Wish List

Product Advantages

  • Scale up your cardiomyocyte yield with a simple, easy-to-follow workflow
  • Expand your hPSC-derived atrial or ventricular cardiomyocytes by up to 70-fold
  • Generate fully functional hPSC-derived cardiomyocytes ready for downstream assays
  • Produce cardiomyocytes with over 90% purity

What's Included

  • STEMdiff™ Cardiomyocyte Expansion Kit (Catalog #100-1109)
    • STEMdiff™ Cardiomyocyte Maintenance Basal Medium, 1 x 490 mL
    • STEMdiff™ Cardiomyocyte Passaging Supplement (100X), 1 x 2.5 mL
    • STEMdiff™ Cardiomyocyte Expansion Supplement (50X), 1 x 10 mL
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.

Overview

Expand early-stage human pluripotent stem cell (hPSC)-derived cardiomyocytes consistently using this serum-free kit. This kit generates a large number of functional and highly pure hPSC-derived cardiomyocytes and is compatible with ventricular or atrial cardiomyocytes generated with STEMdiff™ Ventricular Cardiomyocyte Differentiation Kit or STEMdiff™ Atrial Cardiomyocyte Differentiation Kit, respectively. Compared to the typical method of first expanding large numbers of hPSCs followed by multiple rounds of differentiation to yield high numbers of hPSC-derived cardiomyocytes, the STEMdiff™ Cardiomyocyte Expansion kit allows you to easily reach cardiomyocyte populations in the billions by simply expanding early-stage hPSC-derived cardiomyocytes with a single round of cardiomyocyte differentiation. Using this kit, expanded early-stage hPSC-derived cardiomyocytes retain a stable electrical profile and have cTnT percentages over 90% at passage 5. The expanded hPSC-derived cardiomyocytes are ready for high-throughput drug testing, tissue engineering, and regenerative medicine research.

By using this first-to-market kit to efficiently expand cardiomyocytes, you can save time and resources.

Create a complete, optimized workflow with these compatible STEMdiff™ cardiomyocyte products:

STEMdiff™ Ventricular Cardiomyocyte Differentiation Kit
STEMdiff™ Atrial Cardiomyocyte Differentiation Kit
STEMdiff™ Cardiomyocyte Dissociation Kit
STEMdiff™ Cardiomyocyte Support Medium
STEMdiff™ Cardiomyocyte Freezing Medium
STEMdiff™ Cardiomyocyte Maintenance Kit
Cell Type
Cardiomyocytes, PSC-Derived
Species
Human
Application
Differentiation, Expansion
Brand
STEMdiff
Area of Interest
Disease Modeling, Drug Discovery and Toxicity Testing, Stem Cell Biology, Cell Therapy Development
Formulation Category
Serum-Free

Data Figures

hPSC-derived cardiomyocyte expansion using STEMdiff™ kits. Beating monolayer seen after 11 days.

Figure 1. Workflow for the Expansion of Early-Stage hPSC-Derived Cardiomyocytes Using the STEMdiff™ Cardiomyocyte Expansion Kit

Expansion of early-stage human pluripotent stem cell (hPSC)-derived cardiomyocytes begins with the differentiation of hPSCs to cardiomyocytes using the STEMdiff™ Ventricular Cardiomyocyte Differentiation Kit or the STEMdiff™ Atrial Cardiomyocyte Differentiation Kit. On Day 11 of differentiation, a beating, confluent monolayer of early-stage cardiomyocytes can be observed. These cardiomyocytes are harvested and replated at low density to initiate expansion using STEMdiff™ Cardiomyocyte Expansion Kit. Expanding hPSC-derived cardiomyocytes can be passaged up to 5 times before switching to STEMdiff™ Cardiomyocyte Maintenance Medium for downstream assays.

Representative images: Expansion of ventricular cardiomyocytes using STEMdiff™ Passaging Medium.

Figure 2. Expanding hPSC-Derived Cardiomyocytes Are Confluent One Week After Replating with STEMdiff™ Cardiomyocyte Expansion Kit

Representative images of expanding hPSC-derived ventricular cardiomyocytes after replating at low density (Day 1) using STEMdiff™ Cardiomyocyte Passaging Medium. Cardiomyocyte confluency increases during the 7 day expansion period. On Day 7, a confluent monolayer of beating hPSC-derived cardiomyocytes is observed and the expanded hPSC-derived cardiomyocytes are ready for harvest.

Expansion of hPSC-Derived Cardiomyocytes Across Multiple Cell Lines with STEMdiff™ Cardiomyocyte Expansion Kit

Figure 3. Expansion of hPSC-Derived Cardiomyocytes Across Multiple Cell Lines with STEMdiff™ Cardiomyocyte Expansion Kit

(A) Expansion of hPSC-derived cardiomyocytes was tracked for 5 passages with 4 hPSC lines. Per passage, fold expansion is typically highest in the first 1 – 2 passages. (B) Cumulative fold expansion over 5 passages ranged from 33- to 103-fold expansion and averaged at 72-fold ± 12 (n = 15, 4 hPSC lines).

Cardiomyocyte purity tracked during expansion with STEMdiff™ Expansion Kit. High cTnT expression, 90% purity after 5 passages.

Figure 4. Cardiomyocyte Purity Increases During Expansion Using STEMdiff™ Cardiomyocyte Expansion Kit

Cardiomyocyte purity was tracked during expansion using STEMdiff™ Cardiomyocyte Expansion Kit for 5 passages on 4 hPSC lines. Throughout expansion, hPSC-derived cardiomyocytes express high levels of cardiac troponin T, and on average show an increase in cardiomyocyte purity during expansion. After 5 passages, cardiomyocyte cultures show an average cTnT purity of 90% ± 2% (n = 15).

MEA recordings of post-expanded hPSC-derived cardiomyocytes using STEMdiff™ kits. Stable beat rate observed.

Figure 5. Post-Expanded hPSC-Derived Cardiomyocytes Exhibit Typical Cardiac Electrophysiology and a Stable Beat Profile

Microelectrode Array (MEA) recordings of post-expanded hPSC-derived cardiomyocytes (using STEMdiff™ Cardiomyocyte Expansion Kit) exhibit a stable beat rate across 4 hPSC lines. The post-expanded hPSC-derived cardiomyocytes were replated onto MEA and maintained in STEMdiff™ Cardiomyocyte Maintenance Medium for 1 week. The average beat rate was 12 ± 1 beats per minute (n = 14, 4 hPSC lines).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
100-1109
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
100-1109
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
100-1109
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.